Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 17440952 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | prostate cancer | NA | NA | NA | unclassified | |
| ten human leukocyte antigen (hla)-a24(+) patients with localized prostate cancer received weekly personalized peptide vaccine for six times with positive peptides (up to four kinds of peptides) from 16 kinds of vaccine candidates, followed by a retropubic radical prostatectomy (rrp). | |||||||
| 17574613 | HLA-CLASS I (HLA CLASS II) | prostate cancer | NA | NA | NA | negative | |
| down-regulation of hla class i antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. | |||||||
| 17574613 | HLA-CLASS I (HLA CLASS II) | prostate cancer | NA | NA | NA | lack_of_evidence | |
| the current study shows that the prevalence of hla class i down-regulation is high in prostate cancer but histone deacetylase inhibitors can up-regulate hla class i in lncap cells by up-regulating beta2-microglobulin. | |||||||
| 17574613 | HLA-CLASS I (HLA CLASS II) | prostate cancers | NA | NA | NA | negative | |
| we assessed the frequency of down-regulation of hla class i antigens in a large series of prostate cancer tissues and determined the mechanism of up-regulation by investigating prostate cancer cell lines.materials and immunohistochemical staining for hla class i was done in specimens of 419 prostate cancers. | |||||||
| 17574613 | HLA-CLASS I (HLA CLASS II) | prostate cancers | NA | NA | NA | lack_of_evidence | |
| hla class i was down-regulated in 311 prostate cancers (74.2%) and it significantly correlated with beta2-microglobulin down-regulation and a higher clinical stage. | |||||||
| 17914578 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | prostate cancer | NA | NA | NA | unclassified | |
| new peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic t lymphocytes in human leukocyte antigen-a2+ prostate cancer patients. | |||||||
| 17914578 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | prostate cancer | NA | NA | NA | unclassified | |
| in this study, we attempted to identify ezh2-derived peptides that have the potential to generate cancer-reactive cytotoxic t lymphocytes (ctls) in human leukocyte antigen (hla)-a2+ prostate cancer patients. | |||||||
| 17914578 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| among them, the ezh2 120-128 and ezh2 165-174 peptides effectively induced hla-a2-restricted and cancer-reactive ctls from prostate cancer patients. | |||||||
| 17914578 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| these results indicate that these ezh2 120-128 and ezh2 165-174 peptides could be promising candidates in peptide-based immunotherapy for hla-a2+ prostate cancer patients. | |||||||
| 18814178 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| we used a flow cytometry-based interferon (ifn)-gamma secretion assay with peptide-pulsed c1r-a2 as antigen-presenting cells to analyze whether cd8+ t cells directed against any of 24 hla-a*0201-binding peptides from 15 prostate-associated proteins can be found in the peripheral blood of patients with localized prostate cancer. | |||||||
Copyright 2024